Brief: Gensight Biologics Says Will Require Approx. EUR 14 Million To Finance Its Activities Until July 2024

Gensight Biologics SA

03/01/2024 10:54

Jan 3 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * A SCIENTIFIC ADVICE CONFIRMS UK MHRA COULD ACCEPT A
MARKETING
AUTHORISATION APPLICATION FOR LUMEVOQ® WITH THE MOST RECENT
CLINICAL DATA FROM EXISTING TRIALS (NOT NECESSARILY INCLUDING
RECOVER DATA)
    * PLANS TO FILE AN APPLICATION FOR A MARKETING AUTHORISATION
IN
THE UK IN H2 2024, AIMING FOR A POSSIBLE DECISION BY H2 2025
    * DECISION TO MIX TWO SUCCESSFUL DRUG SUBSTANCE BATCHES INTO
ONE
SINGLE DRUG PRODUCT BATCH; PRODUCT NOW EXPECTED TO BE FULLY
RELEASED IN Q3 2024 (VERSUS EARLY Q2 2024 PREVIOUSLY)
    * EXTENDED CASH RUNWAY TO MID-FEBRUARY 2024
    * ONGOING DISCUSSIONS TO BRIDGE AAC RESUMPTION IN FRANCE IN
Q3
2024; ESTIMATED NEED AMOUNTING TO €14 MILLION

Source text: http://tinyurl.com/yu5br8kh
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))